
ASCO 25 Posters
GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please
GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please
The research addresses the challenge of disease relapse, a primary cause of treatment failure post-hematopoietic stem cell transplantation. By employing next-generation sequencing of cfDNA to monitor donor cell chimerism and minimal residual disease (MRD) early after transplantation, the study identifies patients at increased risk of relapse. This approach allows for potential early intervention with consolidation therapy, aiming to mitigate the risk of treatment failure.
GTC presented abstracts at ASH 2024 GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out
New Paper in Journal of Clinical Pathways GTC has participated in a new paper titled: Bringing Value to Health Care. Read the paper as it
GTC presented abstracts at ASCO 2024 GTC’s posters from 2024 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach
GTC presented abstracts at ASH 2023 GTC’s posters from 2023 Convention of American Society of Hematology are now available to be downloaded. Please reach out
Liquid biopsies are a rapidly evolving diagnostic technology with numerous labs offering commercially available tests today. Most labs have taken an approach of cell-free (cfDNA)
GTC presented abstracts at ASCO 2023 GTC’s posters from 2023 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach
GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune
Combining Longitudinal Real-World Data and Clinical Genomics Data Will Enable a More Precise Approach to Cancer Care and Research NEW YORK – COTA, Inc., an